For well over 15 years Endpoints founding editor John Carroll has written an annual report on the top 15 global pharma companies’ R&D budgets, analyzing their pipelines and reviewing their potential — or lack thereof.
This year, he’s also assembling a panel of research experts to help review results and parse strategies for a massively influential segment of the industry’s research ops. Where are the top 15 companies in biopharma headed and how will that affect the entire industry?
Join us to find out.
08:00, Monday, 12 Oct 2026 + 1 more
08:00, Tuesday, 13 Oct 2026
08:00, Monday, 12 Oct 2026 + 1 more
08:00, Tuesday, 13 Oct 2026
08:00, Tuesday, 13 Oct 2026 + 1 more
08:00, Wednesday, 14 Oct 2026
